Entecavir Treatment Prevents Disease Progression in HBV Related Acute-on-Chronic Liver Failure:Estab

• 作 者: WeiGuo;XipingZhao;DeyingTian;JianxinSong;JunyingQi;QinNing;KeMa;MeifangHan;GuangChen;TaoChen;ZenguangWu;DaofengYang;JiaquanHuang;YuanchengHuang;
• 机 构: Department of Infectious Disease,Tongji Hospital of Tongji Medical College,University of Science and
• 出 处: 第二届全国病毒性肝炎慢性化重症化基础与临床研究进展学术会议
• 发表日期: 2012年期

　　Background/Aims:Hepatitis B related acute-on-chronic liver failure has a poor prognosis with very high mortality.Unfortunately,most prognostic predictive models of liver failure are complicated and offer suboptimal sensitivity.Experience in entecavir-treated patients with HBV-ACLF is limited.This study was designed to evaluate the efficacy and safety of entecavir in patients with HBV-ACLF and to develop a novel model (Tongji prognostic predictory model,TPPM) for prognostic prediction of HBV-ACLF patients.